Scientific Publications

Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma

In this retrospective multicenter cohort study involving 387 patients, median (range) age 63 (17-88) years and 235 (60.7%) were male, with stage III to IV melanomas, researchers determined the incidence, time course, spectrum, and associations of chronic immune-related adverse events (irAEs) arising from adjuvant anti-programmed cell death 1 (anti–PD-1) therapy.

Read More
MRV News
Melanoma News
Archive
Menu